Clinical Trials Logo

Lung Adenocarcinoma clinical trials

View clinical trials related to Lung Adenocarcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06104709 Not yet recruiting - Lung Adenocarcinoma Clinical Trials

Local and Peripheral Immune Responsive Landscape Induced by Local Cryoablation in Patients With Lung Adenocarcinoma

Start date: December 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about local and peripheral immune and metabolic changes in patients with lung adenocarcinoma undergoing cryoablation. The main question it aims to answer are: - local and peripheral immune changes in patients with lung adenocarcinoma undergoing cryoablation. - local and peripheral metabolic changes in patients with lung adenocarcinoma undergoing cryoablation. Peripheral blood, biopsy tissues of patients will be collected at the baseline and after cryoablation. Single-cell sequencing, single-cell immune bank, metabolomics and spatial metabolomics will be used to explore the local and peripheral immune changes and metabolites changes in patients with lung adenocarcinoma before and after cryoablation.

NCT ID: NCT05675033 Not yet recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Start date: January 10, 2023
Phase: Phase 2
Study type: Interventional

In order to further evaluate the efficacy of immunotherapy combined with antivascular therapy in the real world, we used Serpluimab combined with Bevacizumab and platinum-based chemotherapy in previously untreated EGFR/ALK-negative advanced non-squamous NSCLC patients, to evaluate the efficacy and safety of this regimen.

NCT ID: NCT05400304 Not yet recruiting - Lung Adenocarcinoma Clinical Trials

Radiomics Combined With Frozen Section Prediction Model for Spread Through Air Space in Lung Adenocarcinoma

Start date: July 1, 2022
Phase:
Study type: Observational

a multifactorial model combining radiomics with frozen section analysis is a potential biomarker for assessing Spread Through Air Space during surgery, which can provide decision-making support to therapeutic planning for early-stage lung adenocarcinomas.

NCT ID: NCT05279521 Not yet recruiting - Lung Cancer Clinical Trials

The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer.

Start date: March 20, 2022
Phase: N/A
Study type: Interventional

This study concluded that lung rehabilitation exercise programs can improve the psychological distress, self-efficacy, quality of life, six-minute walk distance, muscle strength, and reduce the number of hospitalizations for patients with advanced lung cancer.

NCT ID: NCT04965831 Not yet recruiting - Lung Adenocarcinoma Clinical Trials

Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

Start date: August 1, 2021
Phase: Phase 2
Study type: Interventional

This is a phase II study aimed to assess the efficacy and safety of furmonertinib, a third generation EGFR TKI, as perioperation therapy in stage IIIA-IIIB (N1-N2) resectable NSCLC patients.

NCT ID: NCT04482829 Not yet recruiting - Lung Adenocarcinoma Clinical Trials

TCM in the Treatment of Lung Adenocarcinoma

Start date: September 15, 2020
Phase: N/A
Study type: Interventional

This study is to evaluate the efficacy and safety of Jin-yuan-kang granule in the treatment of lung adenocarcinoma (LUAD) preliminarily, and provide reference for further study.

NCT ID: NCT03486496 Not yet recruiting - Lung Adenocarcinoma Clinical Trials

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

Geber
Start date: June 5, 2018
Phase: Phase 2
Study type: Interventional

Rationale: Advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (del19 or L858R) show an impressive progression-free survival between 9 and 11 months when treated with gefitinib. Combination of gefitinib and berberine could improve efficacy in lung cancer with EGFR mutation in vivo and vitro. The investigators hypothesize that progression-free survival could be improved by combination of gefitinib and berberine.

NCT ID: NCT02951637 Not yet recruiting - Lung Adenocarcinoma Clinical Trials

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Start date: December 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare chemotherapy and gefitinib in combination with gefitinib alone as first-line therapy for adenocarcinoma, in terms of efficacy and safety.

NCT ID: NCT02788058 Not yet recruiting - Lung Adenocarcinoma Clinical Trials

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Start date: May 2016
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and toxicity of patients treated with hypofractionated radiotherapy for limited metastatic NSCLC harboring sensitizing EGFR mutations after first line TKI therapy. An exploratory biomarker analysis in blood and tumor samples is also planned.

NCT ID: NCT02738684 Not yet recruiting - Lung Adenocarcinoma Clinical Trials

A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test

Start date: April 2016
Phase: N/A
Study type: Observational

This project aims to do a small sample exploratory study, to predict EGFR-TKI targeted therapy gefitinib' s efficacy in late stage lung adenocarcinoma patients (phase IIIB or IV), who have negative tissue EGFR gene mutation, positive plasma free nucleic acid EGFR gene.